TriangleNCT01839916 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At 2 years
What was measured
Computed using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% CI.
Analysis population: Patients received at least one DLI Treatment.
Groups in this outcome
Treatment (DLI)
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (DLI) | 36 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (DLI) | 59.7 | Not reported | 44.8 | 79.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 44.8
- upper Limit
- 79.4
- value
- 59.7
- denoms
- counts
- group Id
- OG000
- value
- 36
- units
- Participants
- description
- Computed using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% CI.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Treatment (DLI)
- param Type
- NUMBER
- population Description
- Patients received at least one DLI Treatment.
- reporting Status
- POSTED
- time Frame
- At 2 years
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice